| we | evaluated | efficacy of corticosteroids treatment for cases with 2019-nCoV infection (count: 1) | |
|---|---|
| Over the past month, we collaborated with front-line ICU physicians and firstly evaluated the efficacy of corticosteroids treatment for severe or fatal cases with 2019-nCoV infection in Wuhan.
-- Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020. | |
| data | support | corticosteroids treatment for subgroup of patients with 2019-nCoV (count: 1) | |
| However, our clinical experience and available descriptive data from the therapeutic process of the first 15 critical NCP patients are prone to support corticosteroids treatment for specific subgroup of critically ill patients with 2019-nCoV.
-- Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020. | |
| low-dose corticosteroids treatment | is in | subset of critically ill patients with 2019-nCoV (count: 1) | |
| We endorse the potential benefits from low-dose corticosteroids treatment in a subset of critically ill patients with 2019-nCoV based on existing studies and clinical experience, despite there is no significant improvement in overall survival.
-- Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020. | |
| corticosteroids | is in | 2019-nCoV (count: 1) | |
| 4 Understanding the evidence for harm or benefit from corticosteroids in 2019-nCoV is of immediate clinical importance.
-- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020-02-21. | |
| physicians | have developed | expert consensus statement on use of corticosteroids in 2019-nCoV pneumonia (count: 1) | |
| Given the inconclusive evidence and urgent clinical demand, physicians from the Chinese Thoracic Society have developed an expert consensus statement on the use of corticosteroids in 2019-nCoV pneumonia.
-- On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet. 2020-03-06. | |
| corticosteroids | should | should used in patients with 2019-nCoV pneumonia (count: 1) | |
| According to the expert consensus statement, the following basic principles should be followed when using corticosteroids: (1) the benefits and harms should be carefully weighed before using cortico steroids; (2) corticosteroids should be used prudently in critically ill patients with 2019-nCoV pneumonia; (3) for patients with hypoxaemia due to underlying diseases or who regularly use corticosteroids for chronic diseases, further use of corticosteroids should be cautious; and (4) the dosage should be lowto-moderate (≤0·5-1 mg/kg per day methylprednisolone or equiva lent) and the duration should be short (≤7 days).
-- On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet. 2020-03-06. | |
| We | contributing to | development of expert consensus on use of corticosteroids in patients with 2019-nCoV pneumonia (count: 1) | |
| We thank Zhenshun Cheng, Yang Jin, Min Zhou, Jing Zhang, and Jieming Qu for contributing to the development of the expert consensus on the use of corticosteroids in patients with 2019-nCoV pneumonia.
-- On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet. 2020-03-06. | |
| corticosteroids | exacerbate | COVID-19-associated lung injury (count: 1) | |
| As during previous pandemics (severe acute respiratory syndrome and Middle East respiratory syndrome), corticosteroids are not routinely recommended and might exacerbate COVID-19-associated lung injury.
-- COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020-03-16. | |
| lopinavir-ritonavir | are | drugs included in case management protocols of COVID-19 (count: 1) | |
| Consequently, lopinavir-ritonavir and remdesevir are currently the only anti-viral drugs included in the more severe case management protocols of COVID-19 [10] .
-- reference not found! | |
| corticosteroids | treat | patients with COVID-19 infection (count: 1) | |
| In tertiary hospitals in Hubei province, China, systemic corticosteroids were used to treat severely ill patients with COVID-19 infection who exhibited significant acute pulmonary progression in imaging examinations; however, limited experience has shown that this strategy does not result in significant improvement [14] .
-- reference not found! | |